1. ALLA AKTIER
  2. NYHETER
  3. MAGLE CHEMOSWED

Magle Chemoswed

Nyheter Magle Chemoswed Nyheter alla bolag

Magle Chemoswed Holding Reports Financial Results For Second Quarter 2024

MAR

Magle Group's Q2 report highlights organic sales growth and future market expansion with startegic mergers

Q2 2024 KEY INDICATORS

  • Revenues amounted to 46.0 MSEK (38.1)
  • EBITDA equalled 5.3 MSEK (9.5)
  • Operating profit (EBIT) is 1.3 MSEK (6.3)
  • Earnings per share SEK 0,0 (0,4) per share

 
JAN-JUN 2024 KEY INDICATORS

  • Revenues amounted to 84.2 MSEK (76.7)
  • EBITDA equalled 12.4 MSEK (17.1)
  • Operating profit (EBIT) is 5.6 MSEK (10.6)
  • Earnings per share SEK 0,3 (0,7) per share

 
”Magle's Q2 report shows a planned and expected reduction in net profit due to strategic investments in merging Amniotics and PK Chemicals, and resource allocation for DSM product market entry. Organic sales increased in the quarter, demonstrating our underlying strength by maintaining profitability for the period and year, positioning us for long-term growth and market expansion” says Justin Pierce, CEO

Contacts

Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on www.maglechemoswed.com and https://maglegroup.com/ and www.maglepharmacept.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

This information is information that Magle Chemoswed is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-07-18 08:30 CEST.

Attachments

Interim Report Q2 2024

Datum 2024-07-18, kl 08:30
Källa MFN
Bifogade filer
Interim Report Q2 2024
Affiliate
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet